Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23999524 | 0.91 | KDR (0.34) | KDRMAPKAPK2ALDH1A1GAAMAPT | |
| SCHEMBL26310209 | 0.91 | KDR (0.33) | KDRMAPKAPK2BRAF | |
| SCHEMBL23999907 | 0.87 | MAPKAPK2 (0.42) | KDRMAPKAPK2 | |
| SCHEMBL23999518 | 0.85 | MAPKAPK2 (0.47) | MAPKAPK2PARP1 | |
| SCHEMBL26310233 | 0.83 | KDR (0.42) | KDRMAPKAPK2ALDH1A1GAAMAPT | |
| SCHEMBL23999610 | 0.83 | KDR (0.47) | KDRMAPKAPK2 | |
| SCHEMBL30180419 | 0.83 | KDR (0.47) | KDRMAPKAPK2 | |
| SCHEMBL25826368 | 0.81 | KDR (0.43) | KDRMAPKAPK2 | |
| SCHEMBL25495553 | 0.79 | KDR (0.37) | KDRMAPKAPK2ALDH1A1GAAMAPT | |
| SCHEMBL23999823 | 0.78 | MAPKAPK2 (0.36) | MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | KDR 3433/4885MAPKAPK2 151/4885ALDH1A1 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.